[
  {
    "inputSequence": {
      "header": "unk",
      "SHA512": "2744e34d1152f09e20bfa65eddbffc888e6ba0d42e903788b7a948b42db33164c1b11afce86ecb8c4c9b43de5cc536d3e36f57dfdfe6590d31dc3af7eeb48cfb"
    },
    "subtypeText": "B (2.26%)",
    "validationResults": [],
    "alignedGeneSequences": [
      {
        "firstAA": 1,
        "lastAA": 324,
        "gene": {
          "name": "RT",
          "length": 560
        },
        "mutations": [
          {
            "consensus": "E",
            "position": 6,
            "AAs": "EK",
            "isInsertion": false,
            "isDeletion": false,
            "isApobecDRM": false
          },
          {
            "consensus": "A",
            "position": 62,
            "AAs": "V",
            "isInsertion": false,
            "isDeletion": false,
            "isApobecDRM": false
          },
          {
            "consensus": "D",
            "position": 67,
            "AAs": "DG",
            "isInsertion": false,
            "isDeletion": false,
            "isApobecDRM": false
          },
          {
            "consensus": "T",
            "position": 69,
            "AAs": "N",
            "isInsertion": false,
            "isDeletion": false,
            "isApobecDRM": false
          },
          {
            "consensus": "V",
            "position": 75,
            "AAs": "I",
            "isInsertion": false,
            "isDeletion": false,
            "isApobecDRM": false
          },
          {
            "consensus": "F",
            "position": 77,
            "AAs": "L",
            "isInsertion": false,
            "isDeletion": false,
            "isApobecDRM": false
          },
          {
            "consensus": "K",
            "position": 101,
            "AAs": "KR",
            "isInsertion": false,
            "isDeletion": false,
            "isApobecDRM": false
          },
          {
            "consensus": "K",
            "position": 103,
            "AAs": "N",
            "isInsertion": false,
            "isDeletion": false,
            "isApobecDRM": false
          },
          {
            "consensus": "Y",
            "position": 115,
            "AAs": "F",
            "isInsertion": false,
            "isDeletion": false,
            "isApobecDRM": false
          },
          {
            "consensus": "F",
            "position": 116,
            "AAs": "Y",
            "isInsertion": false,
            "isDeletion": false,
            "isApobecDRM": false
          },
          {
            "consensus": "K",
            "position": 122,
            "AAs": "E",
            "isInsertion": false,
            "isDeletion": false,
            "isApobecDRM": false
          },
          {
            "consensus": "Q",
            "position": 151,
            "AAs": "M",
            "isInsertion": false,
            "isDeletion": false,
            "isApobecDRM": false
          },
          {
            "consensus": "D",
            "position": 177,
            "AAs": "E",
            "isInsertion": false,
            "isDeletion": false,
            "isApobecDRM": false
          },
          {
            "consensus": "Y",
            "position": 181,
            "AAs": "C",
            "isInsertion": false,
            "isDeletion": false,
            "isApobecDRM": false
          },
          {
            "consensus": "M",
            "position": 184,
            "AAs": "V",
            "isInsertion": false,
            "isDeletion": false,
            "isApobecDRM": false
          },
          {
            "consensus": "G",
            "position": 190,
            "AAs": "A",
            "isInsertion": false,
            "isDeletion": false,
            "isApobecDRM": false
          },
          {
            "consensus": "T",
            "position": 200,
            "AAs": "A",
            "isInsertion": false,
            "isDeletion": false,
            "isApobecDRM": false
          },
          {
            "consensus": "I",
            "position": 202,
            "AAs": "V",
            "isInsertion": false,
            "isDeletion": false,
            "isApobecDRM": false
          },
          {
            "consensus": "Q",
            "position": 207,
            "AAs": "E",
            "isInsertion": false,
            "isDeletion": false,
            "isApobecDRM": false
          },
          {
            "consensus": "F",
            "position": 214,
            "AAs": "FL",
            "isInsertion": false,
            "isDeletion": false,
            "isApobecDRM": false
          },
          {
            "consensus": "K",
            "position": 219,
            "AAs": "Q",
            "isInsertion": false,
            "isDeletion": false,
            "isApobecDRM": false
          },
          {
            "consensus": "L",
            "position": 228,
            "AAs": "H",
            "isInsertion": false,
            "isDeletion": false,
            "isApobecDRM": false
          },
          {
            "consensus": "A",
            "position": 272,
            "AAs": "P",
            "isInsertion": false,
            "isDeletion": false,
            "isApobecDRM": false
          }
        ],
        "SDRMs": [
          {
            "text": "D67G"
          },
          {
            "text": "F77L"
          },
          {
            "text": "K103N"
          },
          {
            "text": "Y115F"
          },
          {
            "text": "F116Y"
          },
          {
            "text": "Q151M"
          },
          {
            "text": "Y181C"
          },
          {
            "text": "M184V"
          },
          {
            "text": "G190A"
          },
          {
            "text": "K219Q"
          }
        ],
        "alignedNAs": "CCCATTAGTCCTATTRAAACTGTACCAGTAAAACTAAAGCCAGGAATGGATGGCCCAAAAGTTAAACAATGGCCATTGACAGAAGARAAAATAAAAGCATTAGTAGAAATTTGTACAGAAATGGAAAAGGAAGGGAAGATTTCAAAAATTGGGCCTGAAAATCCATACAATACTCCAGTATTTGTCATAAAGAAAAAAGRCAGCAATAAATGGAGAAAATTAATAGATTTAAGAGAACTTAATAAGAGAACTCAGGACTTCTGGGAAGTTCAATTAGGAATACCACATCCCGCAGGGTTAARAAAGAACAAATCAGTAACAGTACTGGATGTGGGTGATGCATTTTATTCAGTTCCCTTAGATGAAGACTTCAGGAAATATACTGCATTTACTATACCTAGTATAAACAATGAGACACCAGGGATTAGATATCAATACAATGTGCTTCCAATGGGATGGAAAGGATCACCAGCAATATTCCAAAGTAGCATGACAAAAATCTTAGAGCCTTTTAGAAAACAAAATCCAGAAATAGTTATCTGTCAATACGTGGATGATTTGTATGTAGCATCTGACTTAGAAATAGGGCAGCATAGAGCAAAAGTAGAGGAACTGAGAGAACATCTRTTRAGGTGGGGAYTTACCACACCAGACCAAAAACATCAGAAGGAACCTCCATTCCATTGGATGGGTTATGAACTTCAYCCTGATAAATGGACAGTACAGCCTATAGTGCTGCCAGAAAARGACAGYTGGACTGTCAATGACATACAGAAGTTAGTGGGAAAATTGAATTGGGCAAGTCAGATTTACCCAGGGATTAAAGTAAAGCAATTATGTAAACTCCTTAGGGGAACCAAAGCACTAACAGAGGTAATACCTCTAACAGAAGAAGCAGAGCTAGAACTGGCAGAAAACAGGGAGATTCTAAAAGAACCAGTACATGGAGTGTATTATGACCCCTCAAAAGAC",
        "alignedAAs": "PISPIKTVPVKLKPGMDGPKVKQWPLTEEKIKALVEICTEMEKEGKISKIGPENPYNTPVFVIKKKGSNKWRKLIDLRELNKRTQDFWEVQLGIPHPAGLRKNKSVTVLDVGDAFYSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPMGWKGSPAIFQSSMTKILEPFRKQNPEIVICQYVDDLYVASDLEIGQHRAKVEELREHLLRWGLTTPDQKHQKEPPFHWMGYELHPDKWTVQPIVLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVKQLCKLLRGTKALTEVIPLTEEAELELAENREILKEPVHGVYYDPSKD",
        "prettyPairwise": {
          "positionLine": [
            " 1 ",
            " 2 ",
            " 3 ",
            " 4 ",
            " 5 ",
            " 6 ",
            " 7 ",
            " 8 ",
            " 9 ",
            "10 ",
            "11 ",
            "12 ",
            "13 ",
            "14 ",
            "15 ",
            "16 ",
            "17 ",
            "18 ",
            "19 ",
            "20 ",
            "21 ",
            "22 ",
            "23 ",
            "24 ",
            "25 ",
            "26 ",
            "27 ",
            "28 ",
            "29 ",
            "30 ",
            "31 ",
            "32 ",
            "33 ",
            "34 ",
            "35 ",
            "36 ",
            "37 ",
            "38 ",
            "39 ",
            "40 ",
            "41 ",
            "42 ",
            "43 ",
            "44 ",
            "45 ",
            "46 ",
            "47 ",
            "48 ",
            "49 ",
            "50 ",
            "51 ",
            "52 ",
            "53 ",
            "54 ",
            "55 ",
            "56 ",
            "57 ",
            "58 ",
            "59 ",
            "60 ",
            "61 ",
            "62 ",
            "63 ",
            "64 ",
            "65 ",
            "66 ",
            "67 ",
            "68 ",
            "69 ",
            "70 ",
            "71 ",
            "72 ",
            "73 ",
            "74 ",
            "75 ",
            "76 ",
            "77 ",
            "78 ",
            "79 ",
            "80 ",
            "81 ",
            "82 ",
            "83 ",
            "84 ",
            "85 ",
            "86 ",
            "87 ",
            "88 ",
            "89 ",
            "90 ",
            "91 ",
            "92 ",
            "93 ",
            "94 ",
            "95 ",
            "96 ",
            "97 ",
            "98 ",
            "99 ",
            "100",
            "101",
            "102",
            "103",
            "104",
            "105",
            "106",
            "107",
            "108",
            "109",
            "110",
            "111",
            "112",
            "113",
            "114",
            "115",
            "116",
            "117",
            "118",
            "119",
            "120",
            "121",
            "122",
            "123",
            "124",
            "125",
            "126",
            "127",
            "128",
            "129",
            "130",
            "131",
            "132",
            "133",
            "134",
            "135",
            "136",
            "137",
            "138",
            "139",
            "140",
            "141",
            "142",
            "143",
            "144",
            "145",
            "146",
            "147",
            "148",
            "149",
            "150",
            "151",
            "152",
            "153",
            "154",
            "155",
            "156",
            "157",
            "158",
            "159",
            "160",
            "161",
            "162",
            "163",
            "164",
            "165",
            "166",
            "167",
            "168",
            "169",
            "170",
            "171",
            "172",
            "173",
            "174",
            "175",
            "176",
            "177",
            "178",
            "179",
            "180",
            "181",
            "182",
            "183",
            "184",
            "185",
            "186",
            "187",
            "188",
            "189",
            "190",
            "191",
            "192",
            "193",
            "194",
            "195",
            "196",
            "197",
            "198",
            "199",
            "200",
            "201",
            "202",
            "203",
            "204",
            "205",
            "206",
            "207",
            "208",
            "209",
            "210",
            "211",
            "212",
            "213",
            "214",
            "215",
            "216",
            "217",
            "218",
            "219",
            "220",
            "221",
            "222",
            "223",
            "224",
            "225",
            "226",
            "227",
            "228",
            "229",
            "230",
            "231",
            "232",
            "233",
            "234",
            "235",
            "236",
            "237",
            "238",
            "239",
            "240",
            "241",
            "242",
            "243",
            "244",
            "245",
            "246",
            "247",
            "248",
            "249",
            "250",
            "251",
            "252",
            "253",
            "254",
            "255",
            "256",
            "257",
            "258",
            "259",
            "260",
            "261",
            "262",
            "263",
            "264",
            "265",
            "266",
            "267",
            "268",
            "269",
            "270",
            "271",
            "272",
            "273",
            "274",
            "275",
            "276",
            "277",
            "278",
            "279",
            "280",
            "281",
            "282",
            "283",
            "284",
            "285",
            "286",
            "287",
            "288",
            "289",
            "290",
            "291",
            "292",
            "293",
            "294",
            "295",
            "296",
            "297",
            "298",
            "299",
            "300",
            "301",
            "302",
            "303",
            "304",
            "305",
            "306",
            "307",
            "308",
            "309",
            "310",
            "311",
            "312",
            "313",
            "314",
            "315",
            "316",
            "317",
            "318",
            "319",
            "320",
            "321",
            "322",
            "323",
            "324"
          ],
          "refAALine": [
            " P ",
            " I ",
            " S ",
            " P ",
            " I ",
            " E ",
            " T ",
            " V ",
            " P ",
            " V ",
            " K ",
            " L ",
            " K ",
            " P ",
            " G ",
            " M ",
            " D ",
            " G ",
            " P ",
            " K ",
            " V ",
            " K ",
            " Q ",
            " W ",
            " P ",
            " L ",
            " T ",
            " E ",
            " E ",
            " K ",
            " I ",
            " K ",
            " A ",
            " L ",
            " V ",
            " E ",
            " I ",
            " C ",
            " T ",
            " E ",
            " M ",
            " E ",
            " K ",
            " E ",
            " G ",
            " K ",
            " I ",
            " S ",
            " K ",
            " I ",
            " G ",
            " P ",
            " E ",
            " N ",
            " P ",
            " Y ",
            " N ",
            " T ",
            " P ",
            " V ",
            " F ",
            " A ",
            " I ",
            " K ",
            " K ",
            " K ",
            " D ",
            " S ",
            " T ",
            " K ",
            " W ",
            " R ",
            " K ",
            " L ",
            " V ",
            " D ",
            " F ",
            " R ",
            " E ",
            " L ",
            " N ",
            " K ",
            " R ",
            " T ",
            " Q ",
            " D ",
            " F ",
            " W ",
            " E ",
            " V ",
            " Q ",
            " L ",
            " G ",
            " I ",
            " P ",
            " H ",
            " P ",
            " A ",
            " G ",
            " L ",
            " K ",
            " K ",
            " K ",
            " K ",
            " S ",
            " V ",
            " T ",
            " V ",
            " L ",
            " D ",
            " V ",
            " G ",
            " D ",
            " A ",
            " Y ",
            " F ",
            " S ",
            " V ",
            " P ",
            " L ",
            " D ",
            " K ",
            " D ",
            " F ",
            " R ",
            " K ",
            " Y ",
            " T ",
            " A ",
            " F ",
            " T ",
            " I ",
            " P ",
            " S ",
            " I ",
            " N ",
            " N ",
            " E ",
            " T ",
            " P ",
            " G ",
            " I ",
            " R ",
            " Y ",
            " Q ",
            " Y ",
            " N ",
            " V ",
            " L ",
            " P ",
            " Q ",
            " G ",
            " W ",
            " K ",
            " G ",
            " S ",
            " P ",
            " A ",
            " I ",
            " F ",
            " Q ",
            " S ",
            " S ",
            " M ",
            " T ",
            " K ",
            " I ",
            " L ",
            " E ",
            " P ",
            " F ",
            " R ",
            " K ",
            " Q ",
            " N ",
            " P ",
            " D ",
            " I ",
            " V ",
            " I ",
            " Y ",
            " Q ",
            " Y ",
            " M ",
            " D ",
            " D ",
            " L ",
            " Y ",
            " V ",
            " G ",
            " S ",
            " D ",
            " L ",
            " E ",
            " I ",
            " G ",
            " Q ",
            " H ",
            " R ",
            " T ",
            " K ",
            " I ",
            " E ",
            " E ",
            " L ",
            " R ",
            " Q ",
            " H ",
            " L ",
            " L ",
            " R ",
            " W ",
            " G ",
            " F ",
            " T ",
            " T ",
            " P ",
            " D ",
            " K ",
            " K ",
            " H ",
            " Q ",
            " K ",
            " E ",
            " P ",
            " P ",
            " F ",
            " L ",
            " W ",
            " M ",
            " G ",
            " Y ",
            " E ",
            " L ",
            " H ",
            " P ",
            " D ",
            " K ",
            " W ",
            " T ",
            " V ",
            " Q ",
            " P ",
            " I ",
            " V ",
            " L ",
            " P ",
            " E ",
            " K ",
            " D ",
            " S ",
            " W ",
            " T ",
            " V ",
            " N ",
            " D ",
            " I ",
            " Q ",
            " K ",
            " L ",
            " V ",
            " G ",
            " K ",
            " L ",
            " N ",
            " W ",
            " A ",
            " S ",
            " Q ",
            " I ",
            " Y ",
            " A ",
            " G ",
            " I ",
            " K ",
            " V ",
            " K ",
            " Q ",
            " L ",
            " C ",
            " K ",
            " L ",
            " L ",
            " R ",
            " G ",
            " T ",
            " K ",
            " A ",
            " L ",
            " T ",
            " E ",
            " V ",
            " I ",
            " P ",
            " L ",
            " T ",
            " E ",
            " E ",
            " A ",
            " E ",
            " L ",
            " E ",
            " L ",
            " A ",
            " E ",
            " N ",
            " R ",
            " E ",
            " I ",
            " L ",
            " K ",
            " E ",
            " P ",
            " V ",
            " H ",
            " G ",
            " V ",
            " Y ",
            " Y ",
            " D ",
            " P ",
            " S ",
            " K ",
            " D "
          ],
          "alignedNAsLine": [
            "CCC",
            "ATT",
            "AGT",
            "CCT",
            "ATT",
            "RAA",
            "ACT",
            "GTA",
            "CCA",
            "GTA",
            "AAA",
            "CTA",
            "AAG",
            "CCA",
            "GGA",
            "ATG",
            "GAT",
            "GGC",
            "CCA",
            "AAA",
            "GTT",
            "AAA",
            "CAA",
            "TGG",
            "CCA",
            "TTG",
            "ACA",
            "GAA",
            "GAR",
            "AAA",
            "ATA",
            "AAA",
            "GCA",
            "TTA",
            "GTA",
            "GAA",
            "ATT",
            "TGT",
            "ACA",
            "GAA",
            "ATG",
            "GAA",
            "AAG",
            "GAA",
            "GGG",
            "AAG",
            "ATT",
            "TCA",
            "AAA",
            "ATT",
            "GGG",
            "CCT",
            "GAA",
            "AAT",
            "CCA",
            "TAC",
            "AAT",
            "ACT",
            "CCA",
            "GTA",
            "TTT",
            "GTC",
            "ATA",
            "AAG",
            "AAA",
            "AAA",
            "GRC",
            "AGC",
            "AAT",
            "AAA",
            "TGG",
            "AGA",
            "AAA",
            "TTA",
            "ATA",
            "GAT",
            "TTA",
            "AGA",
            "GAA",
            "CTT",
            "AAT",
            "AAG",
            "AGA",
            "ACT",
            "CAG",
            "GAC",
            "TTC",
            "TGG",
            "GAA",
            "GTT",
            "CAA",
            "TTA",
            "GGA",
            "ATA",
            "CCA",
            "CAT",
            "CCC",
            "GCA",
            "GGG",
            "TTA",
            "ARA",
            "AAG",
            "AAC",
            "AAA",
            "TCA",
            "GTA",
            "ACA",
            "GTA",
            "CTG",
            "GAT",
            "GTG",
            "GGT",
            "GAT",
            "GCA",
            "TTT",
            "TAT",
            "TCA",
            "GTT",
            "CCC",
            "TTA",
            "GAT",
            "GAA",
            "GAC",
            "TTC",
            "AGG",
            "AAA",
            "TAT",
            "ACT",
            "GCA",
            "TTT",
            "ACT",
            "ATA",
            "CCT",
            "AGT",
            "ATA",
            "AAC",
            "AAT",
            "GAG",
            "ACA",
            "CCA",
            "GGG",
            "ATT",
            "AGA",
            "TAT",
            "CAA",
            "TAC",
            "AAT",
            "GTG",
            "CTT",
            "CCA",
            "ATG",
            "GGA",
            "TGG",
            "AAA",
            "GGA",
            "TCA",
            "CCA",
            "GCA",
            "ATA",
            "TTC",
            "CAA",
            "AGT",
            "AGC",
            "ATG",
            "ACA",
            "AAA",
            "ATC",
            "TTA",
            "GAG",
            "CCT",
            "TTT",
            "AGA",
            "AAA",
            "CAA",
            "AAT",
            "CCA",
            "GAA",
            "ATA",
            "GTT",
            "ATC",
            "TGT",
            "CAA",
            "TAC",
            "GTG",
            "GAT",
            "GAT",
            "TTG",
            "TAT",
            "GTA",
            "GCA",
            "TCT",
            "GAC",
            "TTA",
            "GAA",
            "ATA",
            "GGG",
            "CAG",
            "CAT",
            "AGA",
            "GCA",
            "AAA",
            "GTA",
            "GAG",
            "GAA",
            "CTG",
            "AGA",
            "GAA",
            "CAT",
            "CTR",
            "TTR",
            "AGG",
            "TGG",
            "GGA",
            "YTT",
            "ACC",
            "ACA",
            "CCA",
            "GAC",
            "CAA",
            "AAA",
            "CAT",
            "CAG",
            "AAG",
            "GAA",
            "CCT",
            "CCA",
            "TTC",
            "CAT",
            "TGG",
            "ATG",
            "GGT",
            "TAT",
            "GAA",
            "CTT",
            "CAY",
            "CCT",
            "GAT",
            "AAA",
            "TGG",
            "ACA",
            "GTA",
            "CAG",
            "CCT",
            "ATA",
            "GTG",
            "CTG",
            "CCA",
            "GAA",
            "AAR",
            "GAC",
            "AGY",
            "TGG",
            "ACT",
            "GTC",
            "AAT",
            "GAC",
            "ATA",
            "CAG",
            "AAG",
            "TTA",
            "GTG",
            "GGA",
            "AAA",
            "TTG",
            "AAT",
            "TGG",
            "GCA",
            "AGT",
            "CAG",
            "ATT",
            "TAC",
            "CCA",
            "GGG",
            "ATT",
            "AAA",
            "GTA",
            "AAG",
            "CAA",
            "TTA",
            "TGT",
            "AAA",
            "CTC",
            "CTT",
            "AGG",
            "GGA",
            "ACC",
            "AAA",
            "GCA",
            "CTA",
            "ACA",
            "GAG",
            "GTA",
            "ATA",
            "CCT",
            "CTA",
            "ACA",
            "GAA",
            "GAA",
            "GCA",
            "GAG",
            "CTA",
            "GAA",
            "CTG",
            "GCA",
            "GAA",
            "AAC",
            "AGG",
            "GAG",
            "ATT",
            "CTA",
            "AAA",
            "GAA",
            "CCA",
            "GTA",
            "CAT",
            "GGA",
            "GTG",
            "TAT",
            "TAT",
            "GAC",
            "CCC",
            "TCA",
            "AAA",
            "GAC"
          ],
          "mutationLine": [
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            "EK ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " V ",
            " - ",
            " - ",
            " - ",
            " - ",
            "DG ",
            " - ",
            " N ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " I ",
            " - ",
            " L ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            "KR ",
            " - ",
            " N ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " F ",
            " Y ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " E ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " M ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " E ",
            " - ",
            " - ",
            " - ",
            " C ",
            " - ",
            " - ",
            " V ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " A ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " A ",
            " - ",
            " V ",
            " - ",
            " - ",
            " - ",
            " - ",
            " E ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            "FL ",
            " - ",
            " - ",
            " - ",
            " - ",
            " Q ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " H ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " P ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - "
          ]
        }
      }
    ],
    "drugResistance": [
      {
        "version": {
          "text": "8.8",
          "publishDate": "2019-02-13"
        },
        "gene": {
          "name": "RT"
        },
        "drugScores": [
          {
            "drugClass": {
              "name": "NRTI"
            },
            "drug": {
              "name": "ABC",
              "displayAbbr": "ABC"
            },
            "score": 180.0,
            "partialScores": [
              {
                "mutations": [
                  {
                    "text": "A62V",
                    "primaryType": "NRTI",
                    "comments": [
                      {
                        "type": "NRTI",
                        "text": "A62V is an accessory mutation that often occurs in combination with the multi-NRTI resistance mutations K65R or Q151M. A62V is widespread in subtype A viruses in former Soviet Union countries but A62 is otherwise non-polymorphic."
                      }
                    ]
                  }
                ],
                "score": 5.0
              },
              {
                "mutations": [
                  {
                    "text": "D67G",
                    "primaryType": "NRTI",
                    "comments": [
                      {
                        "type": "NRTI",
                        "text": "D67N is a non-polymorphic TAM associated with low-level resistance to AZT and d4T. When present with other TAMs, it contributes reduced susceptibility to ABC, ddI, and TDF. D67G/E/S/T/H are non-polymorphic NRTI-selected mutations that also generally occur in viruses with multiple TAMs."
                      }
                    ]
                  }
                ],
                "score": 5.0
              },
              {
                "mutations": [
                  {
                    "text": "V75I",
                    "primaryType": "NRTI",
                    "comments": [
                      {
                        "type": "NRTI",
                        "text": "V75I is a relatively non-polymorphic accessory mutation that often occurs in combination with the multi-NRTI resistance mutation Q151M. When V75I occurs alone its clinical significance is uncertain."
                      }
                    ]
                  }
                ],
                "score": 5.0
              },
              {
                "mutations": [
                  {
                    "text": "F77L",
                    "primaryType": "NRTI",
                    "comments": [
                      {
                        "type": "NRTI",
                        "text": "F77L usually occurs in combination with the multi-NRTI resistance mutation Q151M. When it occurs alone, its clinical significance is uncertain."
                      }
                    ]
                  }
                ],
                "score": 5.0
              },
              {
                "mutations": [
                  {
                    "text": "Y115F",
                    "primaryType": "NRTI",
                    "comments": [
                      {
                        "type": "NRTI",
                        "text": "Y115F causes intermediate resistance to ABC and low-level resistance to TDF."
                      }
                    ]
                  }
                ],
                "score": 60.0
              },
              {
                "mutations": [
                  {
                    "text": "F116Y",
                    "primaryType": "NRTI",
                    "comments": [
                      {
                        "type": "NRTI",
                        "text": "F116Y usually occurs in combination with the multi-NRTI resistance mutation Q151M."
                      }
                    ]
                  }
                ],
                "score": 10.0
              },
              {
                "mutations": [
                  {
                    "text": "Q151M",
                    "primaryType": "NRTI",
                    "comments": [
                      {
                        "type": "NRTI",
                        "text": "Q151M causes intermediate/high-level resistance to AZT, ddI, d4T and ABC and low-level resistance to TDF, 3TC and FTC. In combination with accessory mutations at positions 62, 75, 77, and 116, Q151M confers high-level resistance to AZT, ddI, d4T and ABC and intermediate resistance to TDF, 3TC and FTC."
                      }
                    ]
                  }
                ],
                "score": 60.0
              },
              {
                "mutations": [
                  {
                    "text": "M184V",
                    "primaryType": "NRTI",
                    "comments": [
                      {
                        "type": "NRTI",
                        "text": "M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
                      }
                    ]
                  }
                ],
                "score": 15.0
              },
              {
                "mutations": [
                  {
                    "text": "K219Q",
                    "primaryType": "NRTI",
                    "comments": [
                      {
                        "type": "NRTI",
                        "text": "K219Q/E are accessory TAMS associated with reduced susceptibility to AZT and possibly d4T."
                      }
                    ]
                  }
                ],
                "score": 5.0
              },
              {
                "mutations": [
                  {
                    "text": "F77L",
                    "primaryType": "NRTI",
                    "comments": [
                      {
                        "type": "NRTI",
                        "text": "F77L usually occurs in combination with the multi-NRTI resistance mutation Q151M. When it occurs alone, its clinical significance is uncertain."
                      }
                    ]
                  },
                  {
                    "text": "F116Y",
                    "primaryType": "NRTI",
                    "comments": [
                      {
                        "type": "NRTI",
                        "text": "F116Y usually occurs in combination with the multi-NRTI resistance mutation Q151M."
                      }
                    ]
                  },
                  {
                    "text": "Q151M",
                    "primaryType": "NRTI",
                    "comments": [
                      {
                        "type": "NRTI",
                        "text": "Q151M causes intermediate/high-level resistance to AZT, ddI, d4T and ABC and low-level resistance to TDF, 3TC and FTC. In combination with accessory mutations at positions 62, 75, 77, and 116, Q151M confers high-level resistance to AZT, ddI, d4T and ABC and intermediate resistance to TDF, 3TC and FTC."
                      }
                    ]
                  }
                ],
                "score": 10.0
              }
            ],
            "text": "High-Level Resistance"
          },
          {
            "drugClass": {
              "name": "NRTI"
            },
            "drug": {
              "name": "AZT",
              "displayAbbr": "AZT"
            },
            "score": 120.0,
            "partialScores": [
              {
                "mutations": [
                  {
                    "text": "A62V",
                    "primaryType": "NRTI",
                    "comments": [
                      {
                        "type": "NRTI",
                        "text": "A62V is an accessory mutation that often occurs in combination with the multi-NRTI resistance mutations K65R or Q151M. A62V is widespread in subtype A viruses in former Soviet Union countries but A62 is otherwise non-polymorphic."
                      }
                    ]
                  }
                ],
                "score": 5.0
              },
              {
                "mutations": [
                  {
                    "text": "D67G",
                    "primaryType": "NRTI",
                    "comments": [
                      {
                        "type": "NRTI",
                        "text": "D67N is a non-polymorphic TAM associated with low-level resistance to AZT and d4T. When present with other TAMs, it contributes reduced susceptibility to ABC, ddI, and TDF. D67G/E/S/T/H are non-polymorphic NRTI-selected mutations that also generally occur in viruses with multiple TAMs."
                      }
                    ]
                  }
                ],
                "score": 10.0
              },
              {
                "mutations": [
                  {
                    "text": "V75I",
                    "primaryType": "NRTI",
                    "comments": [
                      {
                        "type": "NRTI",
                        "text": "V75I is a relatively non-polymorphic accessory mutation that often occurs in combination with the multi-NRTI resistance mutation Q151M. When V75I occurs alone its clinical significance is uncertain."
                      }
                    ]
                  }
                ],
                "score": 5.0
              },
              {
                "mutations": [
                  {
                    "text": "F77L",
                    "primaryType": "NRTI",
                    "comments": [
                      {
                        "type": "NRTI",
                        "text": "F77L usually occurs in combination with the multi-NRTI resistance mutation Q151M. When it occurs alone, its clinical significance is uncertain."
                      }
                    ]
                  }
                ],
                "score": 10.0
              },
              {
                "mutations": [
                  {
                    "text": "F116Y",
                    "primaryType": "NRTI",
                    "comments": [
                      {
                        "type": "NRTI",
                        "text": "F116Y usually occurs in combination with the multi-NRTI resistance mutation Q151M."
                      }
                    ]
                  }
                ],
                "score": 10.0
              },
              {
                "mutations": [
                  {
                    "text": "Q151M",
                    "primaryType": "NRTI",
                    "comments": [
                      {
                        "type": "NRTI",
                        "text": "Q151M causes intermediate/high-level resistance to AZT, ddI, d4T and ABC and low-level resistance to TDF, 3TC and FTC. In combination with accessory mutations at positions 62, 75, 77, and 116, Q151M confers high-level resistance to AZT, ddI, d4T and ABC and intermediate resistance to TDF, 3TC and FTC."
                      }
                    ]
                  }
                ],
                "score": 60.0
              },
              {
                "mutations": [
                  {
                    "text": "M184V",
                    "primaryType": "NRTI",
                    "comments": [
                      {
                        "type": "NRTI",
                        "text": "M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
                      }
                    ]
                  }
                ],
                "score": -10.0
              },
              {
                "mutations": [
                  {
                    "text": "K219Q",
                    "primaryType": "NRTI",
                    "comments": [
                      {
                        "type": "NRTI",
                        "text": "K219Q/E are accessory TAMS associated with reduced susceptibility to AZT and possibly d4T."
                      }
                    ]
                  }
                ],
                "score": 10.0
              },
              {
                "mutations": [
                  {
                    "text": "F77L",
                    "primaryType": "NRTI",
                    "comments": [
                      {
                        "type": "NRTI",
                        "text": "F77L usually occurs in combination with the multi-NRTI resistance mutation Q151M. When it occurs alone, its clinical significance is uncertain."
                      }
                    ]
                  },
                  {
                    "text": "F116Y",
                    "primaryType": "NRTI",
                    "comments": [
                      {
                        "type": "NRTI",
                        "text": "F116Y usually occurs in combination with the multi-NRTI resistance mutation Q151M."
                      }
                    ]
                  },
                  {
                    "text": "Q151M",
                    "primaryType": "NRTI",
                    "comments": [
                      {
                        "type": "NRTI",
                        "text": "Q151M causes intermediate/high-level resistance to AZT, ddI, d4T and ABC and low-level resistance to TDF, 3TC and FTC. In combination with accessory mutations at positions 62, 75, 77, and 116, Q151M confers high-level resistance to AZT, ddI, d4T and ABC and intermediate resistance to TDF, 3TC and FTC."
                      }
                    ]
                  }
                ],
                "score": 10.0
              },
              {
                "mutations": [
                  {
                    "text": "Q151M",
                    "primaryType": "NRTI",
                    "comments": [
                      {
                        "type": "NRTI",
                        "text": "Q151M causes intermediate/high-level resistance to AZT, ddI, d4T and ABC and low-level resistance to TDF, 3TC and FTC. In combination with accessory mutations at positions 62, 75, 77, and 116, Q151M confers high-level resistance to AZT, ddI, d4T and ABC and intermediate resistance to TDF, 3TC and FTC."
                      }
                    ]
                  },
                  {
                    "text": "M184V",
                    "primaryType": "NRTI",
                    "comments": [
                      {
                        "type": "NRTI",
                        "text": "M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
                      }
                    ]
                  }
                ],
                "score": 10.0
              }
            ],
            "text": "High-Level Resistance"
          },
          {
            "drugClass": {
              "name": "NRTI"
            },
            "drug": {
              "name": "D4T",
              "displayAbbr": "D4T"
            },
            "score": 120.0,
            "partialScores": [
              {
                "mutations": [
                  {
                    "text": "A62V",
                    "primaryType": "NRTI",
                    "comments": [
                      {
                        "type": "NRTI",
                        "text": "A62V is an accessory mutation that often occurs in combination with the multi-NRTI resistance mutations K65R or Q151M. A62V is widespread in subtype A viruses in former Soviet Union countries but A62 is otherwise non-polymorphic."
                      }
                    ]
                  }
                ],
                "score": 5.0
              },
              {
                "mutations": [
                  {
                    "text": "D67G",
                    "primaryType": "NRTI",
                    "comments": [
                      {
                        "type": "NRTI",
                        "text": "D67N is a non-polymorphic TAM associated with low-level resistance to AZT and d4T. When present with other TAMs, it contributes reduced susceptibility to ABC, ddI, and TDF. D67G/E/S/T/H are non-polymorphic NRTI-selected mutations that also generally occur in viruses with multiple TAMs."
                      }
                    ]
                  }
                ],
                "score": 10.0
              },
              {
                "mutations": [
                  {
                    "text": "V75I",
                    "primaryType": "NRTI",
                    "comments": [
                      {
                        "type": "NRTI",
                        "text": "V75I is a relatively non-polymorphic accessory mutation that often occurs in combination with the multi-NRTI resistance mutation Q151M. When V75I occurs alone its clinical significance is uncertain."
                      }
                    ]
                  }
                ],
                "score": 5.0
              },
              {
                "mutations": [
                  {
                    "text": "F77L",
                    "primaryType": "NRTI",
                    "comments": [
                      {
                        "type": "NRTI",
                        "text": "F77L usually occurs in combination with the multi-NRTI resistance mutation Q151M. When it occurs alone, its clinical significance is uncertain."
                      }
                    ]
                  }
                ],
                "score": 10.0
              },
              {
                "mutations": [
                  {
                    "text": "F116Y",
                    "primaryType": "NRTI",
                    "comments": [
                      {
                        "type": "NRTI",
                        "text": "F116Y usually occurs in combination with the multi-NRTI resistance mutation Q151M."
                      }
                    ]
                  }
                ],
                "score": 10.0
              },
              {
                "mutations": [
                  {
                    "text": "Q151M",
                    "primaryType": "NRTI",
                    "comments": [
                      {
                        "type": "NRTI",
                        "text": "Q151M causes intermediate/high-level resistance to AZT, ddI, d4T and ABC and low-level resistance to TDF, 3TC and FTC. In combination with accessory mutations at positions 62, 75, 77, and 116, Q151M confers high-level resistance to AZT, ddI, d4T and ABC and intermediate resistance to TDF, 3TC and FTC."
                      }
                    ]
                  }
                ],
                "score": 60.0
              },
              {
                "mutations": [
                  {
                    "text": "M184V",
                    "primaryType": "NRTI",
                    "comments": [
                      {
                        "type": "NRTI",
                        "text": "M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
                      }
                    ]
                  }
                ],
                "score": -10.0
              },
              {
                "mutations": [
                  {
                    "text": "K219Q",
                    "primaryType": "NRTI",
                    "comments": [
                      {
                        "type": "NRTI",
                        "text": "K219Q/E are accessory TAMS associated with reduced susceptibility to AZT and possibly d4T."
                      }
                    ]
                  }
                ],
                "score": 10.0
              },
              {
                "mutations": [
                  {
                    "text": "F77L",
                    "primaryType": "NRTI",
                    "comments": [
                      {
                        "type": "NRTI",
                        "text": "F77L usually occurs in combination with the multi-NRTI resistance mutation Q151M. When it occurs alone, its clinical significance is uncertain."
                      }
                    ]
                  },
                  {
                    "text": "F116Y",
                    "primaryType": "NRTI",
                    "comments": [
                      {
                        "type": "NRTI",
                        "text": "F116Y usually occurs in combination with the multi-NRTI resistance mutation Q151M."
                      }
                    ]
                  },
                  {
                    "text": "Q151M",
                    "primaryType": "NRTI",
                    "comments": [
                      {
                        "type": "NRTI",
                        "text": "Q151M causes intermediate/high-level resistance to AZT, ddI, d4T and ABC and low-level resistance to TDF, 3TC and FTC. In combination with accessory mutations at positions 62, 75, 77, and 116, Q151M confers high-level resistance to AZT, ddI, d4T and ABC and intermediate resistance to TDF, 3TC and FTC."
                      }
                    ]
                  }
                ],
                "score": 10.0
              },
              {
                "mutations": [
                  {
                    "text": "Q151M",
                    "primaryType": "NRTI",
                    "comments": [
                      {
                        "type": "NRTI",
                        "text": "Q151M causes intermediate/high-level resistance to AZT, ddI, d4T and ABC and low-level resistance to TDF, 3TC and FTC. In combination with accessory mutations at positions 62, 75, 77, and 116, Q151M confers high-level resistance to AZT, ddI, d4T and ABC and intermediate resistance to TDF, 3TC and FTC."
                      }
                    ]
                  },
                  {
                    "text": "M184V",
                    "primaryType": "NRTI",
                    "comments": [
                      {
                        "type": "NRTI",
                        "text": "M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
                      }
                    ]
                  }
                ],
                "score": 10.0
              }
            ],
            "text": "High-Level Resistance"
          },
          {
            "drugClass": {
              "name": "NRTI"
            },
            "drug": {
              "name": "DDI",
              "displayAbbr": "DDI"
            },
            "score": 120.0,
            "partialScores": [
              {
                "mutations": [
                  {
                    "text": "A62V",
                    "primaryType": "NRTI",
                    "comments": [
                      {
                        "type": "NRTI",
                        "text": "A62V is an accessory mutation that often occurs in combination with the multi-NRTI resistance mutations K65R or Q151M. A62V is widespread in subtype A viruses in former Soviet Union countries but A62 is otherwise non-polymorphic."
                      }
                    ]
                  }
                ],
                "score": 5.0
              },
              {
                "mutations": [
                  {
                    "text": "D67G",
                    "primaryType": "NRTI",
                    "comments": [
                      {
                        "type": "NRTI",
                        "text": "D67N is a non-polymorphic TAM associated with low-level resistance to AZT and d4T. When present with other TAMs, it contributes reduced susceptibility to ABC, ddI, and TDF. D67G/E/S/T/H are non-polymorphic NRTI-selected mutations that also generally occur in viruses with multiple TAMs."
                      }
                    ]
                  }
                ],
                "score": 5.0
              },
              {
                "mutations": [
                  {
                    "text": "V75I",
                    "primaryType": "NRTI",
                    "comments": [
                      {
                        "type": "NRTI",
                        "text": "V75I is a relatively non-polymorphic accessory mutation that often occurs in combination with the multi-NRTI resistance mutation Q151M. When V75I occurs alone its clinical significance is uncertain."
                      }
                    ]
                  }
                ],
                "score": 5.0
              },
              {
                "mutations": [
                  {
                    "text": "F77L",
                    "primaryType": "NRTI",
                    "comments": [
                      {
                        "type": "NRTI",
                        "text": "F77L usually occurs in combination with the multi-NRTI resistance mutation Q151M. When it occurs alone, its clinical significance is uncertain."
                      }
                    ]
                  }
                ],
                "score": 10.0
              },
              {
                "mutations": [
                  {
                    "text": "F116Y",
                    "primaryType": "NRTI",
                    "comments": [
                      {
                        "type": "NRTI",
                        "text": "F116Y usually occurs in combination with the multi-NRTI resistance mutation Q151M."
                      }
                    ]
                  }
                ],
                "score": 10.0
              },
              {
                "mutations": [
                  {
                    "text": "Q151M",
                    "primaryType": "NRTI",
                    "comments": [
                      {
                        "type": "NRTI",
                        "text": "Q151M causes intermediate/high-level resistance to AZT, ddI, d4T and ABC and low-level resistance to TDF, 3TC and FTC. In combination with accessory mutations at positions 62, 75, 77, and 116, Q151M confers high-level resistance to AZT, ddI, d4T and ABC and intermediate resistance to TDF, 3TC and FTC."
                      }
                    ]
                  }
                ],
                "score": 60.0
              },
              {
                "mutations": [
                  {
                    "text": "M184V",
                    "primaryType": "NRTI",
                    "comments": [
                      {
                        "type": "NRTI",
                        "text": "M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
                      }
                    ]
                  }
                ],
                "score": 10.0
              },
              {
                "mutations": [
                  {
                    "text": "K219Q",
                    "primaryType": "NRTI",
                    "comments": [
                      {
                        "type": "NRTI",
                        "text": "K219Q/E are accessory TAMS associated with reduced susceptibility to AZT and possibly d4T."
                      }
                    ]
                  }
                ],
                "score": 5.0
              },
              {
                "mutations": [
                  {
                    "text": "F77L",
                    "primaryType": "NRTI",
                    "comments": [
                      {
                        "type": "NRTI",
                        "text": "F77L usually occurs in combination with the multi-NRTI resistance mutation Q151M. When it occurs alone, its clinical significance is uncertain."
                      }
                    ]
                  },
                  {
                    "text": "F116Y",
                    "primaryType": "NRTI",
                    "comments": [
                      {
                        "type": "NRTI",
                        "text": "F116Y usually occurs in combination with the multi-NRTI resistance mutation Q151M."
                      }
                    ]
                  },
                  {
                    "text": "Q151M",
                    "primaryType": "NRTI",
                    "comments": [
                      {
                        "type": "NRTI",
                        "text": "Q151M causes intermediate/high-level resistance to AZT, ddI, d4T and ABC and low-level resistance to TDF, 3TC and FTC. In combination with accessory mutations at positions 62, 75, 77, and 116, Q151M confers high-level resistance to AZT, ddI, d4T and ABC and intermediate resistance to TDF, 3TC and FTC."
                      }
                    ]
                  }
                ],
                "score": 10.0
              }
            ],
            "text": "High-Level Resistance"
          },
          {
            "drugClass": {
              "name": "NRTI"
            },
            "drug": {
              "name": "FTC",
              "displayAbbr": "FTC"
            },
            "score": 110.0,
            "partialScores": [
              {
                "mutations": [
                  {
                    "text": "A62V",
                    "primaryType": "NRTI",
                    "comments": [
                      {
                        "type": "NRTI",
                        "text": "A62V is an accessory mutation that often occurs in combination with the multi-NRTI resistance mutations K65R or Q151M. A62V is widespread in subtype A viruses in former Soviet Union countries but A62 is otherwise non-polymorphic."
                      }
                    ]
                  }
                ],
                "score": 5.0
              },
              {
                "mutations": [
                  {
                    "text": "V75I",
                    "primaryType": "NRTI",
                    "comments": [
                      {
                        "type": "NRTI",
                        "text": "V75I is a relatively non-polymorphic accessory mutation that often occurs in combination with the multi-NRTI resistance mutation Q151M. When V75I occurs alone its clinical significance is uncertain."
                      }
                    ]
                  }
                ],
                "score": 5.0
              },
              {
                "mutations": [
                  {
                    "text": "F77L",
                    "primaryType": "NRTI",
                    "comments": [
                      {
                        "type": "NRTI",
                        "text": "F77L usually occurs in combination with the multi-NRTI resistance mutation Q151M. When it occurs alone, its clinical significance is uncertain."
                      }
                    ]
                  }
                ],
                "score": 5.0
              },
              {
                "mutations": [
                  {
                    "text": "F116Y",
                    "primaryType": "NRTI",
                    "comments": [
                      {
                        "type": "NRTI",
                        "text": "F116Y usually occurs in combination with the multi-NRTI resistance mutation Q151M."
                      }
                    ]
                  }
                ],
                "score": 5.0
              },
              {
                "mutations": [
                  {
                    "text": "Q151M",
                    "primaryType": "NRTI",
                    "comments": [
                      {
                        "type": "NRTI",
                        "text": "Q151M causes intermediate/high-level resistance to AZT, ddI, d4T and ABC and low-level resistance to TDF, 3TC and FTC. In combination with accessory mutations at positions 62, 75, 77, and 116, Q151M confers high-level resistance to AZT, ddI, d4T and ABC and intermediate resistance to TDF, 3TC and FTC."
                      }
                    ]
                  }
                ],
                "score": 15.0
              },
              {
                "mutations": [
                  {
                    "text": "M184V",
                    "primaryType": "NRTI",
                    "comments": [
                      {
                        "type": "NRTI",
                        "text": "M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
                      }
                    ]
                  }
                ],
                "score": 60.0
              },
              {
                "mutations": [
                  {
                    "text": "F77L",
                    "primaryType": "NRTI",
                    "comments": [
                      {
                        "type": "NRTI",
                        "text": "F77L usually occurs in combination with the multi-NRTI resistance mutation Q151M. When it occurs alone, its clinical significance is uncertain."
                      }
                    ]
                  },
                  {
                    "text": "F116Y",
                    "primaryType": "NRTI",
                    "comments": [
                      {
                        "type": "NRTI",
                        "text": "F116Y usually occurs in combination with the multi-NRTI resistance mutation Q151M."
                      }
                    ]
                  },
                  {
                    "text": "Q151M",
                    "primaryType": "NRTI",
                    "comments": [
                      {
                        "type": "NRTI",
                        "text": "Q151M causes intermediate/high-level resistance to AZT, ddI, d4T and ABC and low-level resistance to TDF, 3TC and FTC. In combination with accessory mutations at positions 62, 75, 77, and 116, Q151M confers high-level resistance to AZT, ddI, d4T and ABC and intermediate resistance to TDF, 3TC and FTC."
                      }
                    ]
                  }
                ],
                "score": 15.0
              }
            ],
            "text": "High-Level Resistance"
          },
          {
            "drugClass": {
              "name": "NRTI"
            },
            "drug": {
              "name": "LMV",
              "displayAbbr": "3TC"
            },
            "score": 110.0,
            "partialScores": [
              {
                "mutations": [
                  {
                    "text": "A62V",
                    "primaryType": "NRTI",
                    "comments": [
                      {
                        "type": "NRTI",
                        "text": "A62V is an accessory mutation that often occurs in combination with the multi-NRTI resistance mutations K65R or Q151M. A62V is widespread in subtype A viruses in former Soviet Union countries but A62 is otherwise non-polymorphic."
                      }
                    ]
                  }
                ],
                "score": 5.0
              },
              {
                "mutations": [
                  {
                    "text": "V75I",
                    "primaryType": "NRTI",
                    "comments": [
                      {
                        "type": "NRTI",
                        "text": "V75I is a relatively non-polymorphic accessory mutation that often occurs in combination with the multi-NRTI resistance mutation Q151M. When V75I occurs alone its clinical significance is uncertain."
                      }
                    ]
                  }
                ],
                "score": 5.0
              },
              {
                "mutations": [
                  {
                    "text": "F77L",
                    "primaryType": "NRTI",
                    "comments": [
                      {
                        "type": "NRTI",
                        "text": "F77L usually occurs in combination with the multi-NRTI resistance mutation Q151M. When it occurs alone, its clinical significance is uncertain."
                      }
                    ]
                  }
                ],
                "score": 5.0
              },
              {
                "mutations": [
                  {
                    "text": "F116Y",
                    "primaryType": "NRTI",
                    "comments": [
                      {
                        "type": "NRTI",
                        "text": "F116Y usually occurs in combination with the multi-NRTI resistance mutation Q151M."
                      }
                    ]
                  }
                ],
                "score": 5.0
              },
              {
                "mutations": [
                  {
                    "text": "Q151M",
                    "primaryType": "NRTI",
                    "comments": [
                      {
                        "type": "NRTI",
                        "text": "Q151M causes intermediate/high-level resistance to AZT, ddI, d4T and ABC and low-level resistance to TDF, 3TC and FTC. In combination with accessory mutations at positions 62, 75, 77, and 116, Q151M confers high-level resistance to AZT, ddI, d4T and ABC and intermediate resistance to TDF, 3TC and FTC."
                      }
                    ]
                  }
                ],
                "score": 15.0
              },
              {
                "mutations": [
                  {
                    "text": "M184V",
                    "primaryType": "NRTI",
                    "comments": [
                      {
                        "type": "NRTI",
                        "text": "M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
                      }
                    ]
                  }
                ],
                "score": 60.0
              },
              {
                "mutations": [
                  {
                    "text": "F77L",
                    "primaryType": "NRTI",
                    "comments": [
                      {
                        "type": "NRTI",
                        "text": "F77L usually occurs in combination with the multi-NRTI resistance mutation Q151M. When it occurs alone, its clinical significance is uncertain."
                      }
                    ]
                  },
                  {
                    "text": "F116Y",
                    "primaryType": "NRTI",
                    "comments": [
                      {
                        "type": "NRTI",
                        "text": "F116Y usually occurs in combination with the multi-NRTI resistance mutation Q151M."
                      }
                    ]
                  },
                  {
                    "text": "Q151M",
                    "primaryType": "NRTI",
                    "comments": [
                      {
                        "type": "NRTI",
                        "text": "Q151M causes intermediate/high-level resistance to AZT, ddI, d4T and ABC and low-level resistance to TDF, 3TC and FTC. In combination with accessory mutations at positions 62, 75, 77, and 116, Q151M confers high-level resistance to AZT, ddI, d4T and ABC and intermediate resistance to TDF, 3TC and FTC."
                      }
                    ]
                  }
                ],
                "score": 15.0
              }
            ],
            "text": "High-Level Resistance"
          },
          {
            "drugClass": {
              "name": "NRTI"
            },
            "drug": {
              "name": "TDF",
              "displayAbbr": "TDF"
            },
            "score": 75.0,
            "partialScores": [
              {
                "mutations": [
                  {
                    "text": "A62V",
                    "primaryType": "NRTI",
                    "comments": [
                      {
                        "type": "NRTI",
                        "text": "A62V is an accessory mutation that often occurs in combination with the multi-NRTI resistance mutations K65R or Q151M. A62V is widespread in subtype A viruses in former Soviet Union countries but A62 is otherwise non-polymorphic."
                      }
                    ]
                  }
                ],
                "score": 5.0
              },
              {
                "mutations": [
                  {
                    "text": "D67G",
                    "primaryType": "NRTI",
                    "comments": [
                      {
                        "type": "NRTI",
                        "text": "D67N is a non-polymorphic TAM associated with low-level resistance to AZT and d4T. When present with other TAMs, it contributes reduced susceptibility to ABC, ddI, and TDF. D67G/E/S/T/H are non-polymorphic NRTI-selected mutations that also generally occur in viruses with multiple TAMs."
                      }
                    ]
                  }
                ],
                "score": 5.0
              },
              {
                "mutations": [
                  {
                    "text": "V75I",
                    "primaryType": "NRTI",
                    "comments": [
                      {
                        "type": "NRTI",
                        "text": "V75I is a relatively non-polymorphic accessory mutation that often occurs in combination with the multi-NRTI resistance mutation Q151M. When V75I occurs alone its clinical significance is uncertain."
                      }
                    ]
                  }
                ],
                "score": 5.0
              },
              {
                "mutations": [
                  {
                    "text": "F77L",
                    "primaryType": "NRTI",
                    "comments": [
                      {
                        "type": "NRTI",
                        "text": "F77L usually occurs in combination with the multi-NRTI resistance mutation Q151M. When it occurs alone, its clinical significance is uncertain."
                      }
                    ]
                  }
                ],
                "score": 5.0
              },
              {
                "mutations": [
                  {
                    "text": "Y115F",
                    "primaryType": "NRTI",
                    "comments": [
                      {
                        "type": "NRTI",
                        "text": "Y115F causes intermediate resistance to ABC and low-level resistance to TDF."
                      }
                    ]
                  }
                ],
                "score": 15.0
              },
              {
                "mutations": [
                  {
                    "text": "F116Y",
                    "primaryType": "NRTI",
                    "comments": [
                      {
                        "type": "NRTI",
                        "text": "F116Y usually occurs in combination with the multi-NRTI resistance mutation Q151M."
                      }
                    ]
                  }
                ],
                "score": 5.0
              },
              {
                "mutations": [
                  {
                    "text": "Q151M",
                    "primaryType": "NRTI",
                    "comments": [
                      {
                        "type": "NRTI",
                        "text": "Q151M causes intermediate/high-level resistance to AZT, ddI, d4T and ABC and low-level resistance to TDF, 3TC and FTC. In combination with accessory mutations at positions 62, 75, 77, and 116, Q151M confers high-level resistance to AZT, ddI, d4T and ABC and intermediate resistance to TDF, 3TC and FTC."
                      }
                    ]
                  }
                ],
                "score": 15.0
              },
              {
                "mutations": [
                  {
                    "text": "M184V",
                    "primaryType": "NRTI",
                    "comments": [
                      {
                        "type": "NRTI",
                        "text": "M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
                      }
                    ]
                  }
                ],
                "score": -10.0
              },
              {
                "mutations": [
                  {
                    "text": "K219Q",
                    "primaryType": "NRTI",
                    "comments": [
                      {
                        "type": "NRTI",
                        "text": "K219Q/E are accessory TAMS associated with reduced susceptibility to AZT and possibly d4T."
                      }
                    ]
                  }
                ],
                "score": 5.0
              },
              {
                "mutations": [
                  {
                    "text": "F77L",
                    "primaryType": "NRTI",
                    "comments": [
                      {
                        "type": "NRTI",
                        "text": "F77L usually occurs in combination with the multi-NRTI resistance mutation Q151M. When it occurs alone, its clinical significance is uncertain."
                      }
                    ]
                  },
                  {
                    "text": "F116Y",
                    "primaryType": "NRTI",
                    "comments": [
                      {
                        "type": "NRTI",
                        "text": "F116Y usually occurs in combination with the multi-NRTI resistance mutation Q151M."
                      }
                    ]
                  },
                  {
                    "text": "Q151M",
                    "primaryType": "NRTI",
                    "comments": [
                      {
                        "type": "NRTI",
                        "text": "Q151M causes intermediate/high-level resistance to AZT, ddI, d4T and ABC and low-level resistance to TDF, 3TC and FTC. In combination with accessory mutations at positions 62, 75, 77, and 116, Q151M confers high-level resistance to AZT, ddI, d4T and ABC and intermediate resistance to TDF, 3TC and FTC."
                      }
                    ]
                  }
                ],
                "score": 15.0
              },
              {
                "mutations": [
                  {
                    "text": "Q151M",
                    "primaryType": "NRTI",
                    "comments": [
                      {
                        "type": "NRTI",
                        "text": "Q151M causes intermediate/high-level resistance to AZT, ddI, d4T and ABC and low-level resistance to TDF, 3TC and FTC. In combination with accessory mutations at positions 62, 75, 77, and 116, Q151M confers high-level resistance to AZT, ddI, d4T and ABC and intermediate resistance to TDF, 3TC and FTC."
                      }
                    ]
                  },
                  {
                    "text": "M184V",
                    "primaryType": "NRTI",
                    "comments": [
                      {
                        "type": "NRTI",
                        "text": "M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
                      }
                    ]
                  }
                ],
                "score": 10.0
              }
            ],
            "text": "High-Level Resistance"
          },
          {
            "drugClass": {
              "name": "NNRTI"
            },
            "drug": {
              "name": "DOR",
              "displayAbbr": "DOR"
            },
            "score": 40.0,
            "partialScores": [
              {
                "mutations": [
                  {
                    "text": "Y181C",
                    "primaryType": "NNRTI",
                    "comments": [
                      {
                        "type": "NNRTI",
                        "text": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by >50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility."
                      }
                    ]
                  }
                ],
                "score": 10.0
              },
              {
                "mutations": [
                  {
                    "text": "K103N",
                    "primaryType": "NNRTI",
                    "comments": [
                      {
                        "type": "NNRTI",
                        "text": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
                      }
                    ]
                  },
                  {
                    "text": "Y181C",
                    "primaryType": "NNRTI",
                    "comments": [
                      {
                        "type": "NNRTI",
                        "text": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by >50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility."
                      }
                    ]
                  }
                ],
                "score": 10.0
              },
              {
                "mutations": [
                  {
                    "text": "Y181C",
                    "primaryType": "NNRTI",
                    "comments": [
                      {
                        "type": "NNRTI",
                        "text": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by >50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility."
                      }
                    ]
                  },
                  {
                    "text": "G190A",
                    "primaryType": "NNRTI",
                    "comments": [
                      {
                        "type": "NNRTI",
                        "text": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
                      }
                    ]
                  }
                ],
                "score": 20.0
              }
            ],
            "text": "Intermediate Resistance"
          },
          {
            "drugClass": {
              "name": "NNRTI"
            },
            "drug": {
              "name": "EFV",
              "displayAbbr": "EFV"
            },
            "score": 135.0,
            "partialScores": [
              {
                "mutations": [
                  {
                    "text": "K103N",
                    "primaryType": "NNRTI",
                    "comments": [
                      {
                        "type": "NNRTI",
                        "text": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
                      }
                    ]
                  }
                ],
                "score": 60.0
              },
              {
                "mutations": [
                  {
                    "text": "Y181C",
                    "primaryType": "NNRTI",
                    "comments": [
                      {
                        "type": "NNRTI",
                        "text": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by >50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility."
                      }
                    ]
                  }
                ],
                "score": 30.0
              },
              {
                "mutations": [
                  {
                    "text": "G190A",
                    "primaryType": "NNRTI",
                    "comments": [
                      {
                        "type": "NNRTI",
                        "text": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
                      }
                    ]
                  }
                ],
                "score": 45.0
              }
            ],
            "text": "High-Level Resistance"
          },
          {
            "drugClass": {
              "name": "NNRTI"
            },
            "drug": {
              "name": "ETR",
              "displayAbbr": "ETR"
            },
            "score": 50.0,
            "partialScores": [
              {
                "mutations": [
                  {
                    "text": "Y181C",
                    "primaryType": "NNRTI",
                    "comments": [
                      {
                        "type": "NNRTI",
                        "text": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by >50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility."
                      }
                    ]
                  }
                ],
                "score": 30.0
              },
              {
                "mutations": [
                  {
                    "text": "G190A",
                    "primaryType": "NNRTI",
                    "comments": [
                      {
                        "type": "NNRTI",
                        "text": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
                      }
                    ]
                  }
                ],
                "score": 10.0
              },
              {
                "mutations": [
                  {
                    "text": "Y181C",
                    "primaryType": "NNRTI",
                    "comments": [
                      {
                        "type": "NNRTI",
                        "text": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by >50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility."
                      }
                    ]
                  },
                  {
                    "text": "G190A",
                    "primaryType": "NNRTI",
                    "comments": [
                      {
                        "type": "NNRTI",
                        "text": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
                      }
                    ]
                  }
                ],
                "score": 10.0
              }
            ],
            "text": "Intermediate Resistance"
          },
          {
            "drugClass": {
              "name": "NNRTI"
            },
            "drug": {
              "name": "NVP",
              "displayAbbr": "NVP"
            },
            "score": 180.0,
            "partialScores": [
              {
                "mutations": [
                  {
                    "text": "K103N",
                    "primaryType": "NNRTI",
                    "comments": [
                      {
                        "type": "NNRTI",
                        "text": "K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
                      }
                    ]
                  }
                ],
                "score": 60.0
              },
              {
                "mutations": [
                  {
                    "text": "Y181C",
                    "primaryType": "NNRTI",
                    "comments": [
                      {
                        "type": "NNRTI",
                        "text": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by >50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility."
                      }
                    ]
                  }
                ],
                "score": 60.0
              },
              {
                "mutations": [
                  {
                    "text": "G190A",
                    "primaryType": "NNRTI",
                    "comments": [
                      {
                        "type": "NNRTI",
                        "text": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
                      }
                    ]
                  }
                ],
                "score": 60.0
              }
            ],
            "text": "High-Level Resistance"
          },
          {
            "drugClass": {
              "name": "NNRTI"
            },
            "drug": {
              "name": "RPV",
              "displayAbbr": "RPV"
            },
            "score": 70.0,
            "partialScores": [
              {
                "mutations": [
                  {
                    "text": "Y181C",
                    "primaryType": "NNRTI",
                    "comments": [
                      {
                        "type": "NNRTI",
                        "text": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by >50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility."
                      }
                    ]
                  }
                ],
                "score": 45.0
              },
              {
                "mutations": [
                  {
                    "text": "G190A",
                    "primaryType": "NNRTI",
                    "comments": [
                      {
                        "type": "NNRTI",
                        "text": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
                      }
                    ]
                  }
                ],
                "score": 15.0
              },
              {
                "mutations": [
                  {
                    "text": "Y181C",
                    "primaryType": "NNRTI",
                    "comments": [
                      {
                        "type": "NNRTI",
                        "text": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by >50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility."
                      }
                    ]
                  },
                  {
                    "text": "G190A",
                    "primaryType": "NNRTI",
                    "comments": [
                      {
                        "type": "NNRTI",
                        "text": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
                      }
                    ]
                  }
                ],
                "score": 10.0
              }
            ],
            "text": "High-Level Resistance"
          }
        ]
      }
    ]
  }
]